KEPHAS PHARMA
ActiveFrom the official registers: KBO 2 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
KEPHAS PHARMA has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €33,505 and a net result of €7,346. Its solvency ranks better than 72% of 25,566 sector peers (NACE 47, financial year 2024). The computed 12-month bankruptcy probability is 1.4% (low).
Overview
Official details
KBO- Status
- Active since 07-11-2022 Normal situation
- Legal form
- Private limited company
- Registered office
- Rue du Cheval Blanc(LUT) 55, 6238 Pont-à-Celles
- Activity
- Retail sale of pharmaceutical products NACE 47730and 2 others
- Establishment unit
- 2.339.469.160 6238 Pont-à-Celles, since 07-11-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 30-12-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.4%
- Gross margin
- €13,925
- ▼ 54.7%
- Turnover
- ≈ €150,000
- estimated
- Profit
- €7,346
- ▼ 68.3%
- Equity
- €33,505
- ▲ 28.1%
- Total assets
- €57,577
- ▲ 23.1%
Score breakdownraises riskCapped at 59: a confirmed filing findingFigures for financial year 2024 (filed on 29-07-2025)1 financial year not filed after the legal deadline; 1 of the last 3 accounts lateFounded in 2022lowers riskLiquidity: current ratio 2.39, cash €34,188Show the evidence
Checked score
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 71% of them on solvency, 84% on liquidity, 50% on profitability and 78% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
The company filed its last 2 accounts on average 63 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (1)
Financials · financial year 2024, micro format
2025 annual accounts not yet filed, deadline passed on 31 July 2026 The financial year closed on 31 December 2025. The accounts are due at the latest 7 months after the close (Companies Code art. 3:10). Source: NBB filings, as of 1 November 2026.
Annual accounts 2024
- Financial year ended
- 31-12-2024
- Filed on
- 29-07-2025
- Format
- micro format
- Reference
- 2025-00321571
2023 to 2024, 2 financial years
The operating result for 2024 is 67% lower than in 2023.
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
The higher the solvency, the better the company absorbs a setback.
A ratio above 1 means the short-term assets cover the short-term debts.
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Retail trade (NACE 47). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio and return on assets (ROA).
Companies with the same profile, two years later
Historical observationIn July 2024, 39,278 companies had the same profile as KEPHAS PHARMA has now. Two years later, 1.8% had gone bankrupt and 95.9% were still going.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
That fits the bankruptcy probability of KEPHAS PHARMA itself: 1.4% within 12 months.
Test of the method
The method was tested on the 497,445 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for KEPHAS PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Other operating charges640/8 | €1,375 | €4,094 | ▲ 198% |
| Gross operating margin9900 | €30,726 | €13,925 | ▼ 54.7% |
| Operating profit (loss)9901 | €29,351 | €9,831 | ▼ 66.5% |
| Financial income75/76B | €0 | €457 | ▲ 2,284× |
| Recurring financial income75 | €0 | €457 | ▲ 2,284× |
| Financial charges65/66B | €223 | €678 | ▲ 204% |
| Recurring financial charges65 | €223 | €678 | ▲ 204% |
| Profit (loss) for the period before taxes9903 | €29,129 | €9,610 | ▼ 67.0% |
| Income taxes67/77 | €5,969 | €2,264 | ▼ 62.1% |
| Profit (loss) for the period9904 | €23,160 | €7,346 | ▼ 68.3% |
| Profit (loss) for the period to be appropriated9905 | €23,160 | €7,346 | ▼ 68.3% |
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €46,790 | €57,577 | ▲ 23.1% |
| Current assets29/58 | €46,790 | €57,577 | ▲ 23.1% |
| Amounts receivable within one year40/41 | €20,388 | €20,852 | ▲ 2.3% |
| Trade receivables40 | €15,977 | €10,863 | ▼ 32.0% |
| Other amounts receivable41 | €4,411 | €9,988 | ▲ 126% |
| Cash at bank and in hand54/58 | €21,070 | €34,188 | ▲ 62.3% |
| Deferred charges and accrued income490/1 | €5,332 | €2,537 | ▼ 52.4% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €46,790 | €57,577 | ▲ 23.1% |
| Equity10/15 | €26,160 | €33,505 | ▲ 28.1% |
| Contributions10/11 | €3,000 | €3,000 | = |
| Reserves13 | €23,160 | €30,505 | ▲ 31.7% |
| Distributable reserves133 | €23,160 | €30,505 | ▲ 31.7% |
| Amounts payable17/49 | €20,630 | €24,071 | ▲ 16.7% |
| Amounts payable within one year42/48 | €20,630 | €24,071 | ▲ 16.7% |
| Trade debts44 | €5,654 | €3,898 | ▼ 31.1% |
| Suppliers440/4 | €5,654 | €3,898 | ▼ 31.1% |
| Taxes, remuneration and social security45 | €14,976 | €20,174 | ▲ 34.7% |
| Taxes450/3 | €14,976 | €20,174 | ▲ 34.7% |
Comparable companies
These companies have the same main activity as KEPHAS PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €48,600 and €64,600, founded between 2020 and 2023.
| Company | Founded | Total assets | Equity | Gross margin | Net result | Financial year |
|---|---|---|---|---|---|---|
| KEPHAS PHARMA Pont-à-Celles | 2022 | €57,577 | €33,505 | €13,925 | €7,346 | 2024 |
| ERAPHAR Haaltert | 2022 | €50,132 | €39,157 | €16,957 | €12,094 | 2025 |
| Prometheus HealthCare Incourt | 2021 | €64,621 | €15,229 | €11,987 | €7,253 | 2025 |
| APOTHEKER LAURA SPIRITUS Linter | 2021 | €62,639 | €6,457 | €11,797 | €6,457 | 2025 |
| Katrien Smets Heist-op-den-Berg | 2022 | €56,328 | €34,808 | €18,249 | €12,472 | 2025 |
| P.H.A. Anderlecht | 2023 | €60,047 | €52,269 | €18,445 | €5,743 | 2025 |
| PHARMELLE Aalst | 2020 | €48,646 | €10,408 | €13,408 | €7,408 | 2025 |
They were chosen from the 3,936 other active companies with that main activity and annual accounts from the past two years. All companies with this main activity
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Board 1
Day-to-day management 1
Mandate history
- Board
- Day-to-day management
| Name | Functions and periods |
|---|---|
| AYELE ATEBA Pierre Romuald |
|
The board according to the articles of association
Board and representation
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alone
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Un ou plusieurs, sans limitation de durée”
Audit, dissolution and liquidation
- Dissolution ruleThe articles set when and by whom the company can be dissolved.
- “Décision assemblée générale, prévues pour modifications aux statuts”
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Quelque cause et à quelque moment que ce soit, faculté assemblée de désigner un ou plusieurs liquidateurs et déterminer pouvoirs et…”
Articles of association, deed of 09-11-2022
Owners and capital
Capital transactions
- AYELE ATEBA Pierre Romuald sole founder · 100% at incorporation
- 09-11-2022 Incorporation · €3,000 · 300 shares
Shares according to the articles of association
Capital, shares and profit
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- One provision in the deed
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Moitié cédant moitié acquéreurs proportionnellement si plusieurs, nullité”
Other provisionsThese rules from the articles cover subjects other than the board, the shares, the purpose and the meetings.
Articles of association, deed of 09-11-2022 (in French)
Group and network
Connections & network
1 current directorThe network starts from the directors of KEPHAS PHARMA. Every other company they run is a node.
History
On 7 November 2022, KEPHAS PHARMA was incorporated as a private limited company by one natural person, with a starting capital of €3,000.12 AYELE ATEBA Pierre Romuald has served as administrateur non statutaire,administrateur délégué et représentant permanent since 2022.3 The company has filed 2 sets of annual accounts, the latest for financial year 2024.4
Acts, filings and financial milestones
09-11
Gazette deed
IncorporationAppointment: AYELE ATEBA Pierre Romuald (administrateur non statutaire,administrateur délégué et représentant permanent) · Founder · Founding capital7 points ▸
- Incorporation, 24-10-2022
- Founder, AYELE ATEBA Pierre Romuald
- Founding capital, €3,000
- Registered office clause, “6238 Luttre,rue du Cheval Blanc,55” (deed in French)
- Board rule, 1, “assemblée” (deed in French)
- Director appointment, AYELE ATEBA Pierre Romuald (administrateur non statutaire,administrateur délégué et représentant permanent)
- Pre-incorporation commitments, “takeover, engagements,obligations et activités entrepris par l'un ou l'autre des comparants au nom et pour compte de la société en formation” (deed in French)
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
Register details
Identity
KBO recordRegistered office and establishments
Activities
NACEBEL 202513 activities
- Toutes les activités qui appartiennent normalement à celles de l'exploitation d'une pharmacie d'officine ouverte au public,y compris toutes les activités qui s'y rapportent directement ou indirectement ou qui s'y rapportent étroitement et donc,entre autres,la préparation magistrale et la vente au détail de médicaments,allo-ou homéopathiques;la fourniture de produits pharmaceutiques,parapharmaceutiques et homéopathiques,de pansements,d'aliments diététiques,d'articles de nutrition infantile et diététique,de produits et articles de soins personnels,de produits de beauté et de soins connexes,de parfumerie et cosmétique,d'articles de parapharmacie et d'optique,le tout au sens le plus large;la liste précédente n'est qu'exemplative et non exhaustive
- La vente,en ce compris la vente en ligne,de tout produit lié de près ou de loin au domaine de la santé humaine et vétérinaire
- Toutes activités liées à la pharmacie en milieu hospitalier
- Toutes missions au sein de structures sanitaires extra officinales et extra hospitalières,telles les centres de vaccination
- La formation et l’enseignement dans les domaines scientifiques et pharmaceutiques
- Toutes missions liées à la santé et à l’hygiène au sein des administrations belges et/ou étrangères
- La recherche et l'étude scientifique,l'obtention,l'acquisition,l'exploitation,la cession,ou la concession de tous brevets,licences,marques,recettes ou autres droits du patrimoine intellectuel,se rapportant aux produits,instruments,ustensiles et appareils utilisés,le conseil,l'expertise et l'étude de marchés en ces matières pour son propre compte ou pour compte de tiers,ainsi qu'accorder toutes licences ou sous licences
- La consultance sous toutes ses formes et en toutes matières,dans le sens le plus large du terme,dans le but de création d'affaires et de la signature de contrats
- Les conseils de gestion en matière d'administration d'officine de pharmacie ainsi que la gestion opérationnelle d'officines pour compte de tiers ou en participation avec un ou plusieurs tiers
- Toutes activités d’une société de patrimoine,y compris celles des marchands de biens et la location et l’exploitation de biens immobiliers propres ou loués
- Toutes activités d’une société de management,y compris l’exercice de mandats d’administrateur et de liquidateur dans d’autres personnes morales
- Toutes activités des sociétés holding,y compris la prise de participations minoritaires ou de contrôle dans des sociétés industrielles ou non,commerciales ou non
- Toutes activités de marketing et de publicité,ainsi que l’exploitation de bureaux de publicité et de droits intellectuels et d’auteur de toute nature
Invoicing and payment
Financial year and general meeting
Accounts at the NBBThe scores and ratios are Checked's own calculations, not a credit decision.
Sites & property
1 establishment unit
Buildings and parcels at the address
1 parcel
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 52042C0120/00C005 | Wallonia | 431 m² | 1 · 157 m² | 10.4 m · 3 |